Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery

被引：0

作者：

Tong, Z. ^{[1
]}

Fu, G. ^{[2
]}

Zhou, F. ^{[2
]}

Liu, X. ^{[3
]}

Xue, X. ^{[4
]}

Zhang, H. ^{[1
]}

Wang, Y. ^{[2
]}

Zhu, X. ^{[1
]}

Gao, Y. ^{[1
]}

Liu, L. ^{[1
]}

Bao, X. ^{[1
]}

Zheng, Y. ^{[1
]}

Fang, W. ^{[1
]}

Zhao, P. ^{[1
]}

Jin, B. ^{[2
]}

机构：

[1] Zhejiang Univ, Dept Med Oncol, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Hangzhou, Peoples R China

[4] Zhejiang Univ, Dept Radiol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.1024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2375P

引用

页码：S1210 / S1210

页数：1